Fig. 5
From: Expression of HLA-DR genes in gliomas: correlation with clinicopathological features and prognosis
Kaplan-Meier survival analysis. a Comparison of the PFS between high and low HLA-DR score groups in patients with LGGs (p = 0.046, log-rank test; p = 0.021, Breslow test). b Comparison of the OS between the two groups in patients with LGGs (p = 0.053, log-rank test; p = 0.029, Breslow test). c Comparison of the PFS between the two groups in patients with LGG oligodendroglial tumors (p = 0.023, log-rank test; p = 0.024, Breslow test). d Comparison of the OS between the two groups in patients with LGG oligodendroglial tumors (p = 0.020, log-rank test; p = 0.021, Breslow test). e Comparison of the PFS between the two groups in patients with LGG astrocytic tumors (p = 0.377, log-rank test; p = 0.078, Breslow test). f Comparison of the OS between the two groups in patients with LGG astrocytic tumors (p = 0.205, log-rank test; p = 0.092, Breslow test). PFS Progression-free survival; OS overall survival; LGG low-grade glioma